Prescriptions of generic antiretroviral drugs in three healthcare centers in the Paris area, France.
Humans
Retrospective Studies
Female
Male
Drugs, Generic
/ therapeutic use
Middle Aged
Paris
HIV Infections
/ drug therapy
Adult
Anti-Retroviral Agents
/ therapeutic use
Drug Prescriptions
/ statistics & numerical data
Aged
Drug Utilization
/ statistics & numerical data
Anti-HIV Agents
/ therapeutic use
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
30
5
2024
Statut:
ppublish
Résumé
In a retrospective study conducted in three hospitals in Paris, generic antiretroviral accounted for 30.2% of all prescriptions. Tenofovir disoproxil/emtricitabine (TDF/FTC) was the most prescribed generic ART (82.3% of generic prescriptions). Generic ART (gART) was more likely to be prescribed to women, to patients less than 50 years, and with recent HIV diagnosis less than 3 years. Physicians prescribed more gART if they were men, older than 55 years or worked at a university teaching hospital.
Identifiants
pubmed: 38814716
doi: 10.1097/QAD.0000000000003899
pii: 00002030-202407010-00022
doi:
Substances chimiques
Drugs, Generic
0
Anti-Retroviral Agents
0
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1269-1272Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Papot E, Landman R, Louni F, Charpentier C, Peytavin G, Certain A, et al. ANRS-GOTA Study Group. Budget impact of antiretroviral therapy in a French clinic cohort. AIDS 2017; 31:1271–1279.
Yazdanpanah Y, Schwarzinger M. Generic antiretroviral drugs and HIV care: an economic review. Méd Mal Infect 2016; 46:67–71.
Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 2013; 158:84–92.
Cour des Comptes. La prévention et la prise en charge du VIH. Communication à la Commission des affaires sociales du Sénat. Paris: Cour des comptes; 2019.
Caisse Nationale d’Assurance Maladie (CNAM). Cartographie médicalisée des dépenses de santé. Poids des pathologies et traitements dans les dépenses de l’Assurance Maladie et prévalences sur le territoire. Données 2020. 2022. Available at: https://data.ameli.fr/pages/data-pathologies/. [Accessed 28 April 2023]
Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d’experts sous la direction du Pr Philippe Morlat et sous l’égide du CNS et de l’ANRS. Paris: CNS; 2018.
EACS Guidelines version 12, October 2023. Available at: https://www.eacsociety.org/media/guidelines-12.0.pdf. [Accessed 10 January 2024]
Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, et al. Nadis Group. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med 2009; 10:504–511.
Giraud J-S, Doisne M, Wai ACH, Majerholc C, Fourn E, Sejean K, et al. De-simplifying single-tablet antiretroviral treatments for cost savings in France: from the patient perspectives to a 6-month follow-up on generics. PLoS One 2020; 15:e0239704.
Krentz H, Campbell S, Gill J. Desimplification of single tablet antiretroviral (ART) regimens—a practical cost-savings strategy?. J Int Assoc Provid AIDS Care 2019; 18:2325958218822304.
Engelhard EAN, Smit C, Vervoort SCJM, Smit PJ, Nieuwkerk PT, Kroon FP, et al. Patients’ willingness to take multiple-tablet antiretroviral therapy regimens for treatment of HIV. Drugs Real World Outcomes 2016; 3:223–230.
Pérez-Stachowski J, Tortajada B, Arco AD, Márquez E, Torre JD la, Nieto M, et al. Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 48 weeks. Infect Dis 2019; 51:691–693.
Suárez-García I, Alejos B, Ruiz-Algueró M, García Yubero C, Moreno C, Bernal E, et al. Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain. J Int AIDS Soc 2021; 24:e25758.
Gianotti N, Poli A, Galli L, Franzin M, Tadini P, Galizzi N, et al. Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients. PLoS One 2017; 12:e0182007.
Jacomet C, Allavena C, Peyrol F, Pereira B, Joubert LM, Bagheri H, et al. Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France. PLoS One 2015; 10:e0117214.
Suárez-García I, Ruiz-Algueró M, García Yubero C, Moreno C, Belza MJ, Estébanez M, et al. Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Physicians’ opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. J Antimicrob Chemother 2020; 75:466–472.
EACS Guidelines version 11.1. October 2022. Available at: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf. [Accessed 10 January 2023]
Waters L, Winston A, Reeves I, Boffito M, Churchill D, Cromarty B, et al. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. HIV Med 2022; 23:3–115.
Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Published Online First: 2022. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv. [Accessed 1 March 2023]
Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA 2023; 329:63–84.
Tribaudeau L, Juillard-Condat B, Taboulet F, Eyvrard F. Le double circuit de dispensation, exemple des traitements antirétroviraux: quelle pertinence?. Ann Pharmaceutiques Françaises 2023.